Galvus licensed as monotherapy for type II diabetes

Galvus (vildagliptin) is now licensed as monotherapy for the treatment of type II diabetes in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

Galvus as monotherapy now an option in type II diabetes
Galvus as monotherapy now an option in type II diabetes

In studies as monotherapy, vildagliptin improved glycaemic control whilst being generally well tolerated compared with placebo, metformin and gliclazide. It had minimal effect on weight gain.

Galvus is also licensed for dual therapy of type II diabetes and has recently been approved for use in patients with renal impairment.

View Galvus drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more